Your browser is no longer supported. Please, upgrade your browser.
RGNX [NASD]
REGENXBIO Inc.
Index- P/E- EPS (ttm)-2.48 Insider Own1.20% Shs Outstand37.34M Perf Week2.94%
Market Cap1.91B Forward P/E- EPS next Y-4.56 Insider Trans-27.62% Shs Float31.89M Perf Month12.08%
Income-91.50M PEG- EPS next Q-0.29 Inst Own89.90% Short Float10.33% Perf Quarter70.93%
Sales144.90M P/S13.15 EPS this Y-194.70% Inst Trans0.20% Short Ratio7.19 Perf Half Y23.28%
Book/sh11.13 P/B4.34 EPS next Y-127.30% ROA-18.70% Target Price60.38 Perf Year-1.55%
Cash/sh6.13 P/C7.89 EPS next 5Y2.00% ROE-21.70% 52W Range20.03 - 54.97 Perf YTD6.57%
Dividend- P/FCF- EPS past 5Y-68.50% ROI-32.50% 52W High-12.06% Beta1.21
Dividend %- Quick Ratio6.10 Sales past 5Y41.90% Gross Margin79.80% 52W Low141.34% ATR2.53
Employees257 Current Ratio6.10 Sales Q/Q572.80% Oper. Margin-73.10% RSI (14)59.43 Volatility5.47% 5.17%
OptionableYes Debt/Eq0.00 EPS Q/Q124.10% Profit Margin-63.10% Rel Volume0.87 Prev Close49.95
ShortableYes LT Debt/Eq0.00 EarningsNov 04 AMC Payout- Avg Volume458.27K Price48.34
Recom2.10 SMA202.73% SMA5020.04% SMA20036.15% Volume398,089 Change-3.22%
Jan-06-21Upgrade Raymond James Outperform → Strong Buy $60
Dec-16-20Initiated UBS Buy $57
Jun-25-20Resumed BofA/Merrill Buy $9
Jun-25-20Resumed BofA/Merrill Buy $60
May-13-20Initiated RBC Capital Mkts Sector Perform $42
Aug-20-19Upgrade SVB Leerink Underperform → Mkt Perform $38 → $37
Jun-18-19Reiterated Chardan Capital Markets Buy $145 → $150
Jun-14-19Resumed Raymond James Outperform
Jun-05-19Reiterated Chardan Capital Markets Buy $127.50 → $145
Feb-25-19Upgrade Evercore ISI In-line → Outperform
Feb-05-19Upgrade Raymond James Outperform → Strong Buy $94
Dec-17-18Reiterated Chardan Capital Markets Buy $127.50
Nov-08-18Reiterated BofA/Merrill Neutral $76 → $84
Aug-08-18Reiterated Chardan Capital Markets Buy $130 → $127.50
Jul-23-18Downgrade BofA/Merrill Buy → Neutral
Jul-10-18Reiterated Chardan Capital Markets Buy $90 → $130
May-09-18Reiterated Barclays Overweight $38 → $48
Apr-09-18Reiterated Chardan Capital Markets Buy $85 → $90
Mar-12-18Downgrade Evercore ISI Outperform → In-line
Feb-13-18Initiated Mizuho Neutral $28
Jan-12-21 04:05PM  
Jan-11-21 07:05AM  
Jan-10-21 02:17AM  
Jan-08-21 07:05AM  
Jan-06-21 04:15PM  
04:01PM  
11:13AM  
07:49AM  
Jan-05-21 04:05PM  
Dec-23-20 08:29AM  
Dec-22-20 04:19PM  
Dec-18-20 09:17PM  
12:14PM  
Dec-17-20 09:42AM  
Dec-10-20 07:05AM  
Dec-09-20 07:05AM  
Dec-01-20 07:05AM  
Nov-23-20 04:05PM  
Nov-10-20 07:00AM  
Nov-06-20 10:24AM  
Nov-05-20 04:05PM  
Nov-04-20 07:30PM  
07:05PM  
05:27PM  
04:05PM  
02:30PM  
Oct-28-20 04:05PM  
Oct-27-20 10:36AM  
07:00AM  
Oct-23-20 02:05PM  
Oct-06-20 05:43PM  
Sep-30-20 07:00AM  
Sep-25-20 07:00AM  
Sep-14-20 09:45AM  
Sep-09-20 07:05AM  
Sep-02-20 04:05PM  
Aug-25-20 08:20AM  
07:00AM  
Aug-06-20 06:25PM  
04:05PM  
Aug-04-20 11:25AM  
07:00AM  
Jul-30-20 04:05PM  
Jul-29-20 12:33PM  
Jul-08-20 07:05AM  
Jun-23-20 07:42PM  
Jun-10-20 07:30AM  
Jun-04-20 08:49AM  
May-12-20 09:06AM  
May-10-20 03:19PM  
May-07-20 08:31PM  
Apr-30-20 04:31PM  
Apr-28-20 05:38PM  
12:33PM  
Apr-27-20 01:55PM  
Apr-23-20 09:12AM  
Apr-22-20 06:30AM  
Mar-31-20 04:05PM  
Mar-13-20 10:02AM  
09:34AM  
Mar-09-20 07:00AM  
02:26AM  
Mar-02-20 08:45AM  
Feb-26-20 07:15PM  
04:05PM  
02:34PM  
Feb-25-20 08:10AM  
Feb-19-20 12:31PM  
Jan-29-20 07:00AM  
Jan-28-20 01:12PM  
Jan-10-20 10:08AM  
Jan-09-20 08:30PM  
07:00AM  
Dec-19-19 04:22PM  
Dec-18-19 07:41AM  
Dec-16-19 09:30AM  
Dec-11-19 03:27PM  
02:07PM  
Dec-04-19 05:00AM  
Nov-06-19 04:15PM  
Nov-05-19 06:25PM  
04:05PM  
Nov-02-19 12:00PM  
Oct-31-19 04:30AM  
Oct-30-19 07:05AM  
Oct-29-19 07:00AM  
Oct-25-19 12:49PM  
09:36AM  
Oct-17-19 07:00AM  
Oct-15-19 02:48PM  
10:57AM  
Oct-11-19 07:15PM  
Oct-10-19 10:11AM  
Oct-06-19 05:15PM  
Oct-02-19 08:31AM  
Oct-01-19 01:43PM  
Sep-30-19 07:00AM  
Sep-19-19 08:29AM  
Sep-13-19 08:44AM  
Sep-09-19 12:58PM  
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Simpson CurranChief Oper. & Tech. OfficerJan 14Option Exercise34.0611,612395,49829,360Jan 14 06:55 PM
Vasista VittalChief Financial OfficerJan 14Sale50.0311,093554,983113,892Jan 14 06:53 PM
Simpson CurranChief Oper. & Tech. OfficerJan 14Sale50.0111,612580,71617,748Jan 14 06:55 PM
Simpson CurranChief Oper. & Tech. OfficerJan 12Option Exercise19.501,70033,15019,448Jan 14 06:55 PM
Christmas Patrick J.Chief Legal OfficerJan 12Option Exercise19.501,37826,87117,750Jan 12 04:48 PM
Simpson CurranChief Oper. & Tech. OfficerJan 12Sale50.031,70085,05117,748Jan 14 06:55 PM
Vasista VittalChief Financial OfficerJan 12Sale50.014,200210,042124,985Jan 14 06:53 PM
Christmas Patrick J.Chief Legal OfficerJan 12Sale49.151,37867,72916,372Jan 12 04:48 PM
Christmas Patrick J.Chief Legal OfficerJan 11Option Exercise14.0210,122141,87926,494Jan 12 04:48 PM
Christmas Patrick J.Chief Legal OfficerJan 11Sale49.0810,122496,78816,372Jan 12 04:48 PM
Christmas Patrick J.Chief Legal OfficerJan 08Option Exercise12.1010,000121,00026,372Jan 12 04:48 PM
Christmas Patrick J.Chief Legal OfficerJan 08Sale47.0610,000470,56516,372Jan 12 04:48 PM
Vasista VittalChief Financial OfficerJan 08Sale47.075,241246,715129,185Jan 11 04:28 PM
Mills Kenneth T.President and CEOJan 07Option Exercise0.851,5001,275283,484Jan 11 04:27 PM
Simpson CurranChief Oper. & Tech. OfficerJan 07Option Exercise19.505,185101,10822,933Jan 11 04:29 PM
Simpson CurranChief Oper. & Tech. OfficerJan 07Sale50.015,185259,30217,748Jan 11 04:29 PM
Vasista VittalChief Financial OfficerJan 07Sale50.0010,998549,900134,426Jan 11 04:28 PM
Mills Kenneth T.President and CEOJan 07Sale50.011,50075,015281,984Jan 11 04:27 PM
Mills Kenneth T.President and CEODec 28Option Exercise0.856,5005,525247,500Dec 30 04:23 PM
Mills Kenneth T.President and CEODec 28Sale48.676,500316,334241,000Dec 30 04:23 PM
Vasista VittalChief Financial OfficerDec 24Sale50.003,376168,800133,024Dec 28 04:18 PM
Mills Kenneth T.President and CEODec 23Option Exercise0.854,5003,825245,500Dec 28 04:17 PM
Vasista VittalChief Financial OfficerDec 23Sale50.0121,1241,056,411136,400Dec 28 04:18 PM
Mills Kenneth T.President and CEODec 23Sale50.004,500225,000241,000Dec 28 04:17 PM
Mills Kenneth T.President and CEODec 16Option Exercise0.8515,00012,750256,000Dec 18 04:20 PM
Mills Kenneth T.President and CEODec 16Sale45.0015,000675,000241,000Dec 18 04:20 PM
Vasista VittalChief Financial OfficerDec 11Sale40.1714,916599,176157,524Dec 14 04:20 PM
Mills Kenneth T.President and CEODec 10Option Exercise0.854,5003,825245,500Dec 14 04:19 PM
Vasista VittalChief Financial OfficerDec 10Sale40.0622,584904,715172,440Dec 14 04:20 PM
Mills Kenneth T.President and CEODec 10Sale40.004,500180,000241,000Dec 14 04:19 PM
Vasista VittalChief Financial OfficerJul 15Option Exercise13.093,25942,660209,974Jul 17 04:22 PM
Vasista VittalChief Financial OfficerJul 15Sale40.1014,950599,495195,024Jul 17 04:22 PM
Vasista VittalChief Financial OfficerMay 11Option Exercise13.095006,545207,215May 12 04:16 PM
Vasista VittalChief Financial OfficerMay 11Sale40.0050020,000206,715May 12 04:16 PM
Vasista VittalChief Financial OfficerMay 08Option Exercise13.092,50032,725213,715May 12 04:16 PM
Vasista VittalChief Financial OfficerMay 08Sale40.187,000281,260206,715May 12 04:16 PM
Vasista VittalChief Financial OfficerApr 24Option Exercise13.093,00039,270223,215Apr 27 04:30 PM
Vasista VittalChief Financial OfficerApr 24Sale40.1112,000481,320211,215Apr 27 04:30 PM
Vasista VittalChief Financial OfficerApr 23Option Exercise13.093,00039,270223,215Apr 27 04:30 PM
Vasista VittalChief Financial OfficerApr 23Sale40.003,000120,000220,215Apr 27 04:30 PM
Vasista VittalChief Financial OfficerMar 31Option Exercise0.8510,0008,500220,215Apr 02 04:22 PM
Simpson CurranSVP, Product Development & CTOFeb 11Option Exercise22.006,633145,92616,512Feb 12 04:27 PM
Simpson CurranSVP, Product Development & CTOFeb 11Sale50.4912,564634,4113,948Feb 12 04:27 PM
HAYDEN DONALD J JRDirectorFeb 10Option Exercise0.8524,80021,08024,800Feb 12 04:22 PM
Vasista VittalChief Financial OfficerFeb 10Option Exercise13.093,00039,270225,021Feb 12 04:24 PM
Simpson CurranSVP, Product Development & CTOFeb 10Option Exercise27.1031,660858,09854,308Feb 12 04:27 PM
Simpson CurranSVP, Product Development & CTOFeb 10Sale50.2244,4292,231,2249,879Feb 12 04:27 PM
Vasista VittalChief Financial OfficerFeb 10Sale50.0714,806741,352210,215Feb 12 04:24 PM
HAYDEN DONALD J JRDirectorFeb 10Sale50.1124,8001,242,7280Feb 12 04:22 PM
HAYDEN DONALD J JRDirectorFeb 05Option Exercise0.852,0001,7002,000Feb 07 04:19 PM
Simpson CurranSVP, Product Development & CTOFeb 05Option Exercise18.085,13792,88628,285Feb 07 04:23 PM
Simpson CurranSVP, Product Development & CTOFeb 05Sale50.005,637281,85022,648Feb 07 04:23 PM
Vasista VittalChief Financial OfficerFeb 05Sale50.0030015,000222,021Feb 07 04:21 PM
HAYDEN DONALD J JRDirectorFeb 05Sale50.002,000100,0000Feb 07 04:19 PM